A Phase 2 interventional study of NVP-1203 and NVP-1203-R in Acute Low Back Pain, sponsored by NVP Healthcare. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2019-09-18.
Sponsored by NVP Healthcare · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Low Back Pain with a site in Korea, Republic of — 9 open to participants now, 11 under way, none of them phase 3. Low Back Pain · Korea, Republic of.
Among the 60 studies in Low Back Pain with a site in Korea, Republic of, this one is the 20th largest by enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2018, is one of 4 in phase 2, and was the 33rd registered.
2,929 studies on the registry are indexed under Low Back Pain; 580 are open to participants now.
Browse Low Back Pain studies →9 of the 60 studies in Low Back Pain with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Keimyung University Dongsan Medical Center · Sites in Korea, Republic of
Ages 20–80
Keimyung University Dongsan Medical Center · Sites in Korea, Republic of
Ages 20–80
Keimyung University Dongsan Medical Center · Sites in Korea, Republic of
Ages 20–80
Jaseng Medical Foundation · Sites in Korea, Republic of
Ages 19–69
Jae Yong Jeon, MD · Sites in Korea, Republic of
Ages 30–65 · Healthy volunteers
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 9 · Phase 4 4
First in 2005; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 91 is above the median of 60 across 2,368 interventional studies indexed under Low Back Pain.
Median enrollment 70 across the 47 interventional studies, 104 across the 12 observational. Of the 37 that completed or were terminated, 3 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 60 have an industry lead sponsor. The 10 most frequent:
NVP Healthcare is the lead sponsor of 22 studies on the registry; 2 are open to participants now.
NVP Healthcare has 4 studies filed under Low Back Pain — fewer than ten, so there is no comparison to draw.
3 of the studies in Low Back Pain with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07058376Jaseng Medical FoundationClinical Research of Effectiveness and Safety of Herbal Medicine Strategy for Chronic Low Back Pain | 2026-12-31 |
| NCT07807839Keimyung University Dongsan Medical CenterStudy of Correlation Between Serum BDNF Levels and Pfirmann Grading and IL- 1β | 2027-08-30 |
| NCT07776366Keimyung University Dongsan Medical CenterStudy of Correlation Between the Level of Intradiscal Periostin Expression and Pfirrmann Grading | 2027-08-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 60 studies in Low Back Pain with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety NVP-1203 in patients with Acute low back pain
This study is a randomized, double-blind, active- and placebo-controlled, parallel, phase II study to evaluate efficacy and safety of NVP-1203 in patients with Acute low back pain
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NVP-1203 plus NVP-1203-R placebo for up to 7 days, oral dose
Drug: NVP-1203 · Drug: NVP-1203-R placebo
NVP-1203-R plus NVP-1203 placebo for up to 7 days, oral dose
Drug: NVP-1203-R · Drug: NVP-1203 placebo
NVP-1203 placebo plus NVP-1203-R placebo for up to 7 days, oral dose
Drug: NVP-1203 placebo · Drug: NVP-1203-R placebo
oral dose for 7 days
oral dose for 7 days
oral dose for 7 days
oral dose for 7 days
VAS Pain Intensity
Improvement in VAS compared to baseline
Time frame: 3, 7 days
Finger to Floor Distance (FFD)
Improvement in FFD compared to baseline
Time frame: 3, 7 days
Oswestry Disability Index(ODI)
Improvement in ODI compared to baseline
Time frame: 3, 7 days
Investigator Global Assessment of Response to Therapy(IGART)
Improvement in IGART compared to baseline
Time frame: 7 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2018 to primary completion in Jan 2019, 11 months.
Of 33 phase 2 interventional studies under Low Back Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: NVP-1203